Vancomycin-resistant enterococci (VRE) are a major cause of healthcare-associated infections (HAIs). However, the clinical significance of VRE colonization and the subsequent risk of VRE infection in hospitalized patients are not fully established. Prolonged hospital stays have been observed in neonates colonized by VRE. The mortality rate in pediatric patients with VRE infections ranges from 0% to 42% in both endemic and outbreak settings, often occurring in VRE-colonized neonates. Host and bacterial factors associated with a worse outcome are not fully understood yet. We describe an outbreak of VRE colonization in 21 newborns admitted to our neonatal intensive care unit in January 2024. Microbiological analyses on rectal swabs were performed using molecular testing and culture. Results: In January, VRE was first detected in the urine culture of a 3-week-old patient, followed by a subsequent positive rectal swab result. In accordance with our infection control policy, all the NICU patients were tested, leading to the identification of another 12 colonized patients. The implementation of molecular testing led to rapid VRE identification and the subsequent isolation of colonized neonates, which promptly contained the outbreak. The median time from NICU admission to colonization was 34 (6–37) days. Only one patient developed a CVC-related bloodstream infection, which was successfully treated with linezolid and CVC removal. No VRE-related deaths occurred, even among three patients who underwent abdominal surgery (one gastroschisis, one incarcerated abdominal hernia, and one umbilical hernia) and one patient with necrotizing enterocolitis. Our data show a low infection rate (4%) among VRE-colonized patients (4%) during a NICU outbreak. The rapid identification of multidrug-resistant genes by molecular testing may be implemented in specific settings to enable timely patient identification, adopt infection control measures, and administer appropriate antimicrobial therapy.
The most optimal treatment for serious Stenotrophomonas maltophilia infections remains undetermined based on current evidence. The evolution of Infectious Diseases Society of America (IDSA) guidance from 2022 to 2024 reflects growing support for combination therapy and a shift away from agents with unfavorable pharmacokinetic/pharmacodynamic profiles, such as tigecycline. No randomized controlled trials (RCTs) have been conducted to date, and existing observational comparative studies have yielded heterogeneous results. Despite efforts to adjust for bias and confounders, definitive conclusions remain elusive, largely due to methodological limitations inherent in retrospective designs, such as immortal time bias. For serious S. maltophilia infections, a multi-arm trial is likely necessary to generate robust evidence; however, challenges, such as large sample size requirements, difficult patient recruitment, and high implementation costs remain significant barriers. To overcome these obstacles, innovative trial designs and analytic approaches have emerged. Target trial emulation, for instance, seeks to approximate RCT-level evidence using observational data. Several other designs aim to improve the flexibility and efficiency of clinical trials, including: multi-arm, multi-stage (MAMS) trial designs; embedding a multi-arm trial within a larger platform trial; an analysis method known as PRACTical method composed of personalized randomization treatment options relevant to individuals; and Bayesian analytic frameworks, enabling simultaneous comparison across multiple treatment arms. As we seek answers to complex clinical dilemmas, such as the life-threatening S. maltophilia infection reported by Qadabashi and colleagues in a recent article in ASM Case Reports (ASM Case Rep 1:e00005-25, 2025, https://doi.org/10.1128/asmcr.00005-25 ), these forward-looking trial designs and analytic methodologies will be critical in shaping the future of evidence-based treatment strategies.
1 January 2025 in Case Reports in Infectious Diseases
Background:Aspergillus endocarditis (AE) is a rare but life‐threatening form of infective endocarditis, accounting for only 0.2% of cases. Despite antifungal and surgical treatment, AE remains a major diagnostic and therapeutic challenge with high mortality rates. Ibrutinib, a Bruton’s tyrosine kinase inhibitor used in the treatment of chronic lymphocytic leukemia (CLL), has been associated with early‐onset invasive aspergillosis. However, no cases of AE have been documented in patients undergoing ibrutinib therapy to date. Case Presentation: A 71‐year‐old man with relapsed CLL on third‐line ibrutinib therapy and a history of arrhythmic cardiomyopathy requiring an implantable cardioverter‐defibrillator (ICD) presented with a six‐month history of fever, cough, and fatigue. On admission, a full‐body computed tomography scan revealed intestinal ischemia and multiple thrombotic occlusions involving the kidney, spleen, and iliac artery. Markedly elevated beta‐D‐glucan and serum galactomannan levels prompted empirical initiation of isavuconazole. Transthoracic echocardiography identified a large vegetation (2.5 × 4 cm) on the mitral valve with ICD lead involvement. Despite urgent surgical intervention—including ICD extraction and mitral valve replacement—the patient succumbed to complications. Intraoperative valve cultures grew Aspergillus fumigatus.Conclusions: This report underscores the severity of AE despite combined surgical and antifungal therapy. Given its high mortality rates, clinicians should maintain a high index of suspicion for AE, particularly in immunocompromised patients or those with a history of cardiac surgery or implanted cardiac devices. Early recognition and aggressive intervention remain essential to improving outcomes.
The recent Mpox virus (MPV) outbreak in Europe and North America, primarily among men who have sex with men (MSM), raised concerns about various transmission sources. We examined patients with Mpox from an urban STI center in Lombardy, Italy, between May and August 2022. Demographic, transmission, and clinical data were collected using a standardized form. Initial and subsequent tests were conducted using the RealStar Orthopoxvirus PCR Kit 1.0 (Altona Diagnostics, Hamburg, Germany) for skin lesions and oropharyngeal swabs. A total of 15 patients were recruited, all MSM, with 40% being HIV-positive. Almost all reported recent unprotected sexual activity. Oropharyngeal symptoms were observed in a minority, and oral cavity lesions were present in 20% of cases. MPV DNA was detected in skin lesions of 93% of patients and in oropharyngeal swabs of 87%. Skin samples exhibited a higher viral load than pharyngeal samples, with the latter persisting longer. Prospective follow-up of 11 individuals revealed an average pharyngeal persistence of 5.3 days beyond skin lesion clearance, reaching up to 80 days in an immunosuppressed case. Our findings indicate that MPV replication can persist in the pharynx asymptomatically and for an extended period.
1 September 2025 in Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Progressive multifocal leukoencephalopathy (PML) can rarely occur in individuals with occult immunosuppression. Here, we describe the case of an adult man who presented with PML, in whom CD4+ lymphocytopenia and hypogammaglobulinemia were subsequently identified, leading to a diagnosis of late-onset combined immunodeficiency. Intravenous immunoglobulin replacement therapy was initiated. His clinical course, though complicated by immune reconstitution inflammatory syndrome, was favorable.
2 February 2026 in Journal of Antimicrobial Chemotherapy
Background: Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has been associated with reduced transaminase level among people with HIV (PWH), with and without HBV. It is unclear whether the effect is mediated by HBV serostatus. Methods: We conducted a longitudinal observational study of PWH who switched from TDF to TAF between 2016 and 2023. A mixed-effects model with random intercepts assessed the effect of the switch on transaminases, including an interaction term for HBV status: chronic hepatitis B (HBsAg+), possible occult HBV infection (pOBI; HBsAg−/HBcAb+) and no HBV. Results: Among 727 individuals, 7% had chronic hepatitis B and 35% had pOBI. Switching to TAF was associated with a significant ALT decrease (β −3.5 UI/mL, 95%CI: −5.2 to −1.9). Compared to HBV-negative individuals, individuals with chronic hepatitis B experienced steeper ALT reduction (β −7.5, 95%CI: −11.8 to −3.2), while pOBI was associated with a non-significant reduction (β −1.9; 95%CI: −4.4–0.6; P = 0.133). These findings persisted after adjusting for other predictors of transaminase levels. TAF was also associated with accelerated weight gain (+0.75 kg/year, 95% CI: 0.63–0.87) and a transient drop in the Hepatic Steatosis Index (−0.22; 95% CI: −0.38 to −0.06) followed by an annual increase thereafter (+0.18/year; 95% CI: 0.10–0.27). Conclusions: Switching from TDF to TAF is associated with modest but statistically significant ALT reduction in PWH, especially in HBsAg + individuals. Our findings suggest that TAF may represent a favourable option in this subgroup, although potential metabolic consequences warrant close monitoring.